口腔科

订阅

MedSci主页 / 所有栏目 / 口腔科

Clin Oral Invest：不同混合技术和放置方法对MTA的X射线分析的影响

2018-04-25 MedSci MedSci原创

MTA混合技术
关注

本研究的目的是评估各种混合技术的效果，以及使用X射线衍射（XRD）分析超声波对三氧化二铁聚集体（MTA）水合作用的影响。

本研究的目的是评估各种混合技术的效果，以及使用X射线衍射（XRD）分析超声波对三氧化二铁聚集体（MTA）水合作用的影响。

将1克ProRoot MTA，MTA Angelus粉末与0.34克蒸馏水混合。通过在4500rpm下胶囊机械混合30秒或通过手动混合，然后施加3.22MPa的压制压力1分钟。以最小的压力将混合物转移到XRD样本架中。一半的样本采用间接的超声波活化。所有标本在37℃和100％湿度下孵育4天，通过XRD分析。使用国际衍射数据中心（ICDD）的搜索匹配软件完成相位识别。

结果：所有样本均包含硅酸三钙，碳酸钙和氧化铋。在所有ProRoot标本中形成氢氧化钙相，而在MTA Angelus组中，仅在样本中机械混合并且通过超声处理才发现。

在MTA的水合特性方面，机械混合+超声处理并不具有显着的缺点。

原始出处：

F. B. Basturk， et al. X-ray diffraction analysis of MTA mixed and placed with various techniques.Clinical Oral Investigations. 2018 May. doi：10.1007/s00784-017-2241-9

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051131, encodeId=f206205113101, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Oct 26 16:08:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700346, encodeId=27eb1e00346ac, content=<a href='/topic/show?id=b673188e56a' target=_blank style='color:#2F92EE;'>#X射线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18875, encryptionId=b673188e56a, topicName=X射线)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f930056270, createdName=medsci256, createdTime=Sat Mar 16 14:08:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020415, encodeId=dc49202041547, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jun 13 22:08:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368038, encodeId=b7921368038a0, content=<a href='/topic/show?id=de4912308e7' target=_blank style='color:#2F92EE;'>#MTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12308, encryptionId=de4912308e7, topicName=MTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb3a261, createdName=liuxiaona, createdTime=Fri Apr 27 08:08:00 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
    2018-10-26 xiangyuzhou971

    #EST#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2051131, encodeId=f206205113101, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Oct 26 16:08:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700346, encodeId=27eb1e00346ac, content=<a href='/topic/show?id=b673188e56a' target=_blank style='color:#2F92EE;'>#X射线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18875, encryptionId=b673188e56a, topicName=X射线)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f930056270, createdName=medsci256, createdTime=Sat Mar 16 14:08:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020415, encodeId=dc49202041547, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jun 13 22:08:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368038, encodeId=b7921368038a0, content=<a href='/topic/show?id=de4912308e7' target=_blank style='color:#2F92EE;'>#MTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12308, encryptionId=de4912308e7, topicName=MTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb3a261, createdName=liuxiaona, createdTime=Fri Apr 27 08:08:00 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
    2019-03-16 medsci256

    #X射线#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2051131, encodeId=f206205113101, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Oct 26 16:08:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700346, encodeId=27eb1e00346ac, content=<a href='/topic/show?id=b673188e56a' target=_blank style='color:#2F92EE;'>#X射线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18875, encryptionId=b673188e56a, topicName=X射线)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f930056270, createdName=medsci256, createdTime=Sat Mar 16 14:08:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020415, encodeId=dc49202041547, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jun 13 22:08:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368038, encodeId=b7921368038a0, content=<a href='/topic/show?id=de4912308e7' target=_blank style='color:#2F92EE;'>#MTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12308, encryptionId=de4912308e7, topicName=MTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb3a261, createdName=liuxiaona, createdTime=Fri Apr 27 08:08:00 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
    2018-06-13 heli0118

    #Oral#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2051131, encodeId=f206205113101, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Oct 26 16:08:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700346, encodeId=27eb1e00346ac, content=<a href='/topic/show?id=b673188e56a' target=_blank style='color:#2F92EE;'>#X射线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18875, encryptionId=b673188e56a, topicName=X射线)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f930056270, createdName=medsci256, createdTime=Sat Mar 16 14:08:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020415, encodeId=dc49202041547, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jun 13 22:08:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368038, encodeId=b7921368038a0, content=<a href='/topic/show?id=de4912308e7' target=_blank style='color:#2F92EE;'>#MTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12308, encryptionId=de4912308e7, topicName=MTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb3a261, createdName=liuxiaona, createdTime=Fri Apr 27 08:08:00 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
    2018-04-27 liuxiaona

    #MTA#

    0

相关资讯

J Endod：使用ProRoot MTA或Biodentine对6-18岁龋致露髓患者恒牙实施直接盖髓术的疗效观察

这篇研究的目的是为了比较使用ProRoot MTA或Biodentine对6-18岁因龋露髓患者的恒牙实施直接盖髓术(DPC)的成功率，并评估牙齿变色情况。研究选取59例因龋暴露的恒牙，诊断包括：牙髓活力正常、可复性牙髓炎或不可复性牙髓炎、早期的根尖周炎以及暴露尺寸不大于2.5 mm的患牙。每名患者只有1颗因龋暴露的牙齿，随机使用ProRoot MTA (n = 30)或Biodentine (n

Clin Oral Investig：Micro-CT评估2种根充技术对Vertucci II型近中根管内MTA充填形成的空隙差异

这篇研究的目的是为了比较2种MTA充填技术，手动压实和超声活化的手动MTA压实与加热垂直充填(WVC)技术对下颌第一磨牙Vertucci II型近中根管的封闭效果。

J Endod：MTA根尖充填厚度对未发育完成牙齿抗断裂性的影响

这篇研究的目的是在模拟未发育完成的牙齿内根尖充填不同厚度的MTA，比较其抗断裂性差异。

J Endod：不同治疗选择对不成熟牙齿生物力学的影响：一项有限元应力分析

不成熟牙齿(IT)依据其牙齿的活力不同，可以选择多种治疗方法进行处理。这篇有限元应力分析的目的是为了评估不同治疗程序对不成熟牙齿3维模型应力的影响。

J Periodontal Res：MTA提高了小鼠牙周组织损伤的愈合反应

三氧化矿物凝聚体（MTA）是在牙髓治疗中使用的生物材料，促进组织再生。在这项研究中，我们评估了转基因小鼠模型和小鼠间充质祖细胞体外分化的组织损伤后，MTA对牙周韧带（PDL）和周围组织愈合的影响。

盘点：近期对硅酸钙类充填材料-MTA的应用一览

Mineral Trioxide Aggregrate(MTA)自1998年起开始应用于牙科治疗中。与传统的充填、盖髓等材料相比，MTA具有良好的生物相容性，可以防止细菌微漏的发生，促进组织再生，使牙周组织恢复正常。近年来，广泛应用于根尖闭合、牙槽骨水平以下的穿孔、再吸收缺限、充填根尖以及用作盖髓材料等。在此，梅斯小编整理了近段时间对于MTA应用的重要研究一览。【1】J Endod：使用The